The Fifth Circuit Court of Appeals has ruled that the abortion drug mifepristone can no longer be distributed by mail, requiring in-person clinical dispensing across the US.This decision by three conservative judges effectively overrides the common practice of remote prescribing that expanded significantly after the 2022 Supreme Court reversal of Roe v. Wade.The mandate immediately restricts access to medication abortion, particularly impacting patients in states with restrictive reproductive healthcare laws.